Navigation Links
Half of prostate cancers could potentially benefit from new type of cancer drugs, U-M study finds
Date:5/18/2011

ANN ARBOR, Mich. About half of prostate cancers have a genetic anomaly that appears to make tumor cells responsive to a new class of cancer-fighting drugs, a new study from the University of Michigan Comprehensive Cancer Center finds.

The drugs, called PARP inhibitors, are currently being tested in breast cancer patients with mutations in the BRCA1 and BRCA2 genes, which are found in up to 10 percent of all breast cancers.

Half of prostate cancers have a genomic rearrangement that causes the fusion of two genes called TMPRSS2 and ERG. This gene fusion, believed to be the triggering event of prostate cancer, was initially discovered in 2005 by U-M researchers led by Arul Chinnaiyan, M.D., Ph.D.

"This type of gene fusion occurs in about 50 percent of prostate cancers, but the genes involved have been notoriously difficult to target therapeutically. We found that instead of targeting the gene fusion product directly, we could block the function of critical interacting partners, such as PARP1," says Chinnaiyan, a Howard Hughes Medical Institute researcher, director of the Michigan Center for Translational Pathology and S.P. Hicks Professor of Pathology at the U-M Medical School.

Chinnaiyan is the senior author of the current study, which appears in the May 17 issue of Cancer Cell.

"Our studies suggest that the total population of patients who could benefit from PARP inhibition could be significantly expanded," says Chad Brenner, Ph.D. candidate at U-M, who is the first author on the study.

Working with prostate cancer models in cell lines and mice, researchers found that therapies using the PARP inhibitor Olaparib helped shrink tumors expressing the TMPRSS2:ERG gene fusion and blocked the ability of tumors to spread. Olaparib had no effect on tumors that did not have the gene fusion.

PARP inhibitors are not currently approved by the U.S. Food and Drug Administration, but initial trials in breast cancer patients indicate they can be administered safely and are well-tolerated.

Study authors Maha Hussain, M.D., and Felix Y. Feng, M.D., are currently working on two clinical trials based on these study findings to test if the TMPRSS2:ERG gene fusion could be used as to predict response to treatments, including a PARP inhibitor. These studies are not yet recruiting participants.


'/>"/>

Contact: Nicole Fawcett
nfawcett@umich.edu
734-764-2220
University of Michigan Health System
Source:Eurekalert

Related medicine news :

1. Advance Toward Test for Aggressive Prostate Cancer
2. DASH FOR DAD Race Series Coming to 11 Cities to Raise Prostate Cancer Awareness
3. Jim Huber to Serve as National Spokesman for Know Your Score: Fight Prostate Campaign at Myrtle Beach Golf Holiday in August
4. Few differences in outcomes between open and laparoscopic prostate surgery
5. Two Surgical Methods Equally Successful for Prostate Cancer
6. Genetic Mutation Linked to Prostate Cancer in Blacks
7. Statins May Benefit Prostate Cancer Patients
8. Demand For Mobile Prostate Cancer Brachytherapy Vendor Programs Continues Into 2010
9. Be a Star Athlete in the Fight Against Prostate Cancer
10. Do men with early prostate cancer commit suicide more frequently?
11. Effective prostate cancer treatment discovery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... ... February 05, 2016 , ... At its annual meeting held last ... Chairman of the National Board of Directors. Mr. McDermott succeeds former APDA Chairman, Fred ... Leslie A. Chambers , APDA President and CEO. “Pat has tirelessly served APDA ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... Stuart ... tattoo technology, the PicoSure. Designed to provide the most effective tattoo removal today, Dr. ... with unmatched results. , Developed by Cynosure, the PicoSure has been approved by the ...
(Date:2/5/2016)... ... February 05, 2016 , ... Colorize is ... one drop zone to the next using Colorize's dynamic moving camera. Colorize is perfect ... package includes a 3D slideshow environment with 1 to 5 focus points per scene, ...
(Date:2/5/2016)... , ... February 05, 2016 , ... Health and wellness ... relevant to individuals in the event they are experiencing an illness. Migraines are a ... Americans that are afflicted with migraines would not wish the pain on their worst ...
(Date:2/5/2016)... ... 2016 , ... On June 9-10, Las Vegas will host ... (CME) event presented by the Association for Comprehensive Care in Rare Diseases (ACCORD). ... mission is to provide education, tools, and resources to primary care clinicians that ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... Bernstein Liebhard LLP today announced that a securities class ... for the District of Arizona on ... or entities who purchased common shares of Insys Therapeutics Inc. ... 3, 2015 through January 25, 2016 (the "Class Period").  The ... of the Securities Exchange Act of 1934.  ...
(Date:2/4/2016)... , Feb. 4, 2016 Global Immunology ... market to drive long-term market growth Summary ... set of chronic disorders that affect 5–7% of ... terms of their symptoms and key patient demographics, ... of immune pathways and an inappropriate immune response. ...
(Date:2/4/2016)... SPRING, Md. , Feb. 4, 2016 In ... Califf , the FDA,s Deputy Commissioner for Medical Products and ... action plan to reassess the agency,s approach to opioid medications. ... epidemic, while still providing patients in pain access to effective ... The FDA will: , Re-examine the risk-benefit paradigm ...
Breaking Medicine Technology: